DiamiR Announces Collaborative Poster Presentation by Alzheimer's Association Small Company Consortium at the 2015 Alzheimer's Association International Conference

MONMOUTH JUNCTION, NJ--(Marketwired - July 16, 2015) - DiamiR Biosciences, a developer of innovative tests for detection and monitoring of neurodegenerative diseases, announced today that the company's Chief Executive Officer, Dr. Kira Sheinerman, co-authored a poster presentation on behalf of the Alzheimer's Association Small Company Consortium (AASCC). The poster focused on opportunities and challenges facing small companies targeting Alzheimer's disease will be presented at the 2015 Alzheimer's Association International Conference in Washington, DC.

Session: Developing Topics, Poster #6209
Poster Title: P4-280: Maximizing the Potential of Small Companies in Alzheimer's Disease Research: Challenges and Opportunities
Date: Wednesday, July 22
Time: 9:30 AM - 4:15 PM
Location: Walter E. Washington Convention Center, Exhibit Hall D

The recent creation of the Alzheimer's Association Small Company Consortium (AASCC) has been facilitated by the Alzheimer's Association to increase the effectiveness of small companies in diagnostic, therapeutic, and service sectors focusing on advancing the Alzheimer's field. The AASCC currently includes 20 member companies. Modeled after other successful consortia, the AASCC will focus on streamlining dialogue between companies, fostering collaborations, and sharing certain resources and information.

About AAIC
The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. As a part of the Association's research program, AAIC serves as a catalyst for generating new knowledge about Alzheimer's and fostering a vital and collegial research community.

About DiamiR Biosciences
DiamiR is a privately held molecular diagnostics company focused on developing and commercializing minimally invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer's disease, and other neurodegenerative and neurological conditions. The proprietary technology is based on quantitative analysis of brain-enriched microRNA signatures in plasma and can be used for screening, patient stratification as well as disease and treatment monitoring. For more information, please visit the company's website at www.diamirbio.com.

Please Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.

Contact Information:


Kira Sheinerman, PhD, MBA